These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20881939)

  • 1. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease.
    Reed BY; Masoumi A; Elhassan E; McFann K; Cadnapaphornchai MA; Maahs DM; Snell-Bergeon JK; Schrier RW
    Kidney Int; 2011 Jan; 79(1):128-34. PubMed ID: 20881939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA
    Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis in autosomal-dominant polycystic kidney disease.
    Bello-Reuss E; Holubec K; Rajaraman S
    Kidney Int; 2001 Jul; 60(1):37-45. PubMed ID: 11422734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
    King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Dec; 64(6):2214-21. PubMed ID: 14633145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis and autosomal dominant polycystic kidney disease.
    Huang JL; Woolf AS; Long DA
    Pediatr Nephrol; 2013 Sep; 28(9):1749-55. PubMed ID: 22990303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease.
    Bae K; Park B; Sun H; Wang J; Tao C; Chapman AB; Torres VE; Grantham JJ; Mrug M; Bennett WM; Flessner MF; Landsittel DP; Bae KT;
    Clin J Am Soc Nephrol; 2013 Jul; 8(7):1089-97. PubMed ID: 23520042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.
    Cadnapaphornchai MA; George DM; McFann K; Wang W; Gitomer B; Strain JD; Schrier RW
    Clin J Am Soc Nephrol; 2014 May; 9(5):889-96. PubMed ID: 24721893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.
    Zheng D; Wolfe M; Cowley BD; Wallace DP; Yamaguchi T; Grantham JJ
    J Am Soc Nephrol; 2003 Oct; 14(10):2588-95. PubMed ID: 14514736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
    BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
    Chapman AB
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.
    Leierer J; Perco P; Hofer B; Eder S; Dzien A; Kerschbaum J; Rudnicki M; Mayer G
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease.
    Ozkurt S; Dogan I; Ozcan O; Fidan N; Bozaci I; Yilmaz B; Bilgin M
    Int Urol Nephrol; 2019 Jul; 51(7):1191-1197. PubMed ID: 31012038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
    Nadar SK; Blann A; Beevers DG; Lip GY
    J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.